ObsEva S.A.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Michael Brown
- Full Time Employees
- 48
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Chemin des Aulx, 12 Geneva Switzerland 1228
- IPO Date
- Jul 13, 2018
- CIK
- 0001685316
- Website
- obseva.com
- Similar Companies
- Business
- ObsEva SA (OBSV) is a Swiss-based clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics addressing serious conditions in women's reproductive health and pregnancy, including uterine fibroids, endometriosis, preterm labor, and infertility; its pipeline features linzagolix, an oral GnRH receptor antagonist for uterine fibroids and endometriosis-associated pain, nolasiban (OBE001), an oral oxytocin receptor antagonist for improving IVF/ICSI pregnancy rates and preterm labor, and ebopiprant, a prostaglandin F2alpha receptor antagonist for preterm labor. Founded in 2012 and headquartered in Plan-les-Ouates, Geneva, Switzerland, the company operates globally with a strategic emphasis on women's health segments lacking adequate treatment options. In recent developments, ObsEva delisted from Nasdaq effective March 2023 and from the SIX Swiss Exchange, consolidated operations in Switzerland amid a strategic reorganization and wind-down process, recovered full worldwide rights to nolasiban, sold its ebopiprant license to XOMA for up to $113 million, retired $31 million in debt while refinancing $11 million, and secured dismissal of moratorium proceedings following compliance with Nasdaq equity rules.
Reviewing ObsEva (NASDAQ:OBSV) & ProMetic Life Sciences (OTCMKTS:PFSCF)
Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
ObsEva Announces Update on Board of Directors
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
Geneva Court Grants Temporary Moratorium to ObsEva
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
Organon Returns Ebopiprant to XOMA
ObsEva Files half Year 2023 Financial Statements
ObsEva Recovers Full Worldwide Rights on Nolasiban
What Do Penny Stocks Offer Over Blue Chips?
The Most Important Penny Stocks Trading Indicators
Penny Stocks Trading: How News Plays a Role
Why Is ObsEva (OBSV) Stock Up 93% Today?
Why Is ObsEva (OBSV) Stock Up 61% Today?
Why ObsEva (OBSV) Stock Is Down 36% Today
ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates
Hot Penny Stocks For Your Buy List in September? 3 to Watch
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
Why Is ObsEva (OBSV) Stock Down 70% Today?